Full genome ultra-deep pyrosequencing associates G-to-A hypermutation of the hepatitis B virus genome with the natural progression of hepatitis B

Journal of Viral Hepatitis

Volumn 20, Issue 12, 2013, Pages 882-889

  Beggel, B ^a   Munk C ^b   Daumer M ^c   Hauck, K ^b   Haussinger D ^b   Lengauer, T ^a   Erhardt, A ^b  

^a MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^b Department of Orthopedic Surgery   (Germany)

^c Laboratories Thiele   (Germany)

Author keywords

APOBEC3G; fibrosis; HBV; hypermutation; pyrosequencing

Indexed keywords

CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; DINUCLEOTIDE; HEPATITIS B(E) ANTIGEN;

ADULT; AGED; ARTICLE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PYROSEQUENCING; SEQUENCE ANALYSIS; ULTRA DEEP PYROSEQUENCING; VIRUS GENOME;

APOBEC3G; FIBROSIS; HBV; HYPERMUTATION; PYROSEQUENCING;

ADOLESCENT; ADULT; AGED; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; YOUNG ADULT;

EID: 84887618632     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12110     Document Type: Article

References (39)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST,. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30 (12): 2212-2219.
2. Brunetto MR, Giarin MM, Oliveri F, et al,. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci USA 1991; 88 (10): 4186-4190.
3. Carman WF, Jacyna MR, Hadziyannis S, et al,. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2 (8663): 588-591.
4. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH,. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996; 70 (9): 5845-5851.
5. Scaglioni PP, Melegari M, Wands JR,. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology 1997; 233 (2): 374-381.
6. Noguchi C, Hiraga N, Mori N, et al,. Dual effect of APOBEC3G on Hepatitis B virus. J Gen Virol 2007; 88 (Pt 2): 432-440.
7. Bonvin M, Achermann F, Greeve I, et al,. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 2006; 43 (6): 1364-1374.
8. Sasada A, Takaori-Kondo A, Shirakawa K, et al,. APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology 2005; 2: 32.
9. Thomas DC, Voronin YA, Nikolenko GN, Chen J, Hu WS, Pathak VK,. Determination of the ex vivo rates of human immunodeficiency virus type 1 reverse transcription by using novel strand-specific amplification analysis. J Virol 2007; 81 (9): 4798-4807.
10. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH,. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 2004; 14 (15): 1392-1396.
11. Harris RS, Bishop KN, Sheehy AM, et al,. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113 (6): 803-809.
12. Bonvin M, Greeve J,. Hepatitis B: modern concepts in pathogenesis-APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus. Curr Opin Infect Dis 2008; 21 (3): 298-303.
13. Chiu YL, Greene WC,. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol 2008; 26: 317-353.
14. Baumert TF, Rösler C, Malim MH, von Weizsäcker F,. Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology 2007; 46 (3): 682-689.
15. Köck J, Blum HE,. Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. J Gen Virol 2008; 89 (Pt 5): 1184-1191.
16. Rösler C, Köck J, Kann M, et al,. APOBEC-mediated interference with hepadnavirus production. Hepatology 2005; 42 (2): 301-309.
17. Nguyen DH, Gummuluru S, Hu J,. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol 2007; 81 (9): 4465-4472.
18. Turelli P, Mangeat B, Jost S, Vianin S, Trono D,. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004; 303 (5665): 1829.
19. Jost S, Turelli P, Mangeat B, Protzer U, Trono D,. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J Virol 2007; 81 (19): 10588-10596.
20. Sarkis PT, Ying S, Xu R, Yu XF,. STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha. J Immunol 2006; 177 (7): 4530-4540.
21. Tanaka Y, Marusawa H, Seno H, et al,. Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes. Biochem Biophys Res Commun 2006; 341 (2): 314-319.
22. Vartanian JP, Henry M, Marchio A, et al,. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog 2010; 6 (5): e1000928.
23. Suspène R, Guétard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP,. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA 2005; 102 (23): 8321-8326.
24. Günther S, Sommer G, Plikat U, et al,. Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G->A hypermutation. Virology 1997; 235 (1): 104-108.
25. Noguchi C, Ishino H, Tsuge M, et al,. G to A hypermutation of hepatitis B virus. Hepatology 2005; 41 (3): 626-633.
26. Noguchi C, Imamura M, Tsuge M, et al,. G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection. J Infect Dis 2009; 199 (11): 1599-1607.
27. Marcellin P, Lau GK, Bonino F, et al,. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351 (12): 1206-1217.
28. Lau GK, Piratvisuth T, Luo KX, et al,. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352 (26): 2682-2695.
29. Rose PP, Korber BT,. Detecting hypermutations in viral sequences with an emphasis on G -> A hypermutation. Bioinformatics 2000; 16 (4): 400-401.
30. Reuman EC, Margeridon-Thermet S, Caudill HB, et al,. A classification model for G-to-A hypermutation in hepatitis B virus ultra-deep pyrosequencing reads. Bioinformatics 2010; 26 (23): 2929-2932.
31. Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS,. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol 2004; 337 (3): 585-596.
32. Henry M, Guétard D, Suspène R, Rusniok C, Wain-Hobson S, Vartanian JP,. Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G. PLoS ONE 2009; 4 (1): e4277.
33. Pham P, Bransteitter R, Petruska J, Goodman MF,. Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature 2003; 424 (6944): 103-107.
34. Robinson WS, Clayton DA, Greenman RL,. DNA of a human hepatitis B virus candidate. J Virol 1974; 14 (2): 384-391.
35. Summers J, O'Connell A, Millman I,. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc Natl Acad Sci USA 1975; 72 (11): 4597-4601.
36. Nassal M,. Hepatitis B viruses: reverse transcription a different way. Virus Res 2008; 2: 235-249.
37. Delius H, Gough NM, Cameron CH, Murray K,. Structure of the hepatitis B virus genome. J Virol 1983; 47 (2): 337-343.
38. Chu CJ, Keeffe EB, Han SH, et al,. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38 (3): 619-628.
39. Hussain M, Chu CJ, Sablon E, Lok AS,. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol 2003; 41 (8): 3699-3705.